A Pre-Approval Information Exchange (PIE) Webinar, presented by Alnylam Pharmaceuticals, Inc.

Transthyretin amyloidosis (ATTR) is an underdiagnosed, progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the heart, nerves, and gastrointestinal tract. Please join Alnylam Pharmaceuticals as we review the disease state, clinical symptoms and epidemiology for the Cardiomyopathy manifestation of the disease followed by a review of the study results for the Phase 3 HELIOS-B trial.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Ferring Pharmaceuticals, Inc.

SI-6603 is an investigational product being evaluated for the treatment of radicular leg pain associated with lumbar disc herniation. This pre-approval information exchange (PIE) presentation includes disease overview, an overview of SI-6603 including MOA and pivotal study data along with anticipated timing and access details.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation state and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Abbvie. 

One of the main goals of acute treatment of migraine is freedom from pain and associated symptoms without recurrence. It is therefore important that every person with migraine, regardless of migraine frequency, be offered a migraine specific treatment that has freedom from pain data, freedom from associated symptom data and evidence that the treatment can prevent a moderate to severe migraine attack. The objective for this webinar is to review the migraine disease state and phases of a migraine attack, and outline clinical data as a treatment option for the acute treatment of migraine.

A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. 

Join a comprehensive webinar that will enhance your decision-making for people living with schizophrenia. This webinar will delve into a disease overview of schizophrenia, shedding light on the often overlooked cognitive symptom domain and its significant clinical and economic burden. The webinar will also uncover the latest understanding of the biological mechanisms and explore a potential new treatment approach to specifically target cognitive symptoms associated with schizophrenia. 

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®. This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by GSK. 

Lupus nephritis (LN) is a severe complication of lupus that may lead to significant chronic kidney disease and potentially end stage kidney disease (ESKD). African American Patients with LN are at a higher risk of developing ESKD. Early and accurate diagnosis and testing are key strategies in providing optimal patient care. Evaluation of the needs of the affected community through an interdisciplinary and integrated care management approach may address the gap in inequitable access to care. This presentation and roundtable discussion will be structured to help understand what strategies can be implemented to support patients that do not have access to optimal and equitable care.

A Science & Innovation Webinar, presented by Family Heart Foundation. 

The Family Heart Foundation is a non-profit organization dedicated to research, education, and advocacy, and as part of ongoing research efforts, has examined the state of LDL-C control among 38M Americans at high and very high-risk for cardiovascular disease in the proprietary Family Heart Database. This session will provide an update on current LDL-C treatment guidelines, Lp(a) screening recommendations, and key findings and insights from an analysis of the Family Heart database.